Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Recruiting · NCT06175000 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response | primary central nervous system lymphoma | Recruiting | Phase 2 | 2026-09-23 | NCT06175000 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Providence Health & Services | 35 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute | Seattle | United States | 1 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Pennsylvania State University | Hershey | United States | 9 |
| Providence Health & Services; Providence Neurological Specialties | Portland | United States | 1 |
| University of Vermont | Burlington | United States | 9 |
| University of Virginia | Charlottesville | United States | 136 |